Foresite Capital Fund II, L.P.'s Net Worth
$251 Million
Who is Foresite Capital Fund II, L.P.?
Foresite Capital Fund II, L.P. has an estimated net worth of $251 Million. This is based on reported shares across multiple companies, which include 10x Genomics, Inc., AERIE PHARMACEUTICALS INC, and Aimmune Therapeutics, Inc..
SEC CIK
Foresite Capital Fund II, L.P.'s CIK is 0001594914
Past Insider Trading and Trends
2019 was Foresite Capital Fund II, L.P.'s most active year for acquiring shares with 19 total transactions. Foresite Capital Fund II, L.P.'s most active month to acquire stocks was the month of July. 2020 was Foresite Capital Fund II, L.P.'s most active year for disposing of shares, totalling 23 transactions. Foresite Capital Fund II, L.P.'s most active month to dispose stocks was the month of April. 2019 saw Foresite Capital Fund II, L.P. paying a total of $29,125,039.68 for 15,003,104 shares, this is the most they've acquired in one year. In 2020 Foresite Capital Fund II, L.P. cashed out on 17,443,746 shares for a total of $177,508,500.00, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
10x Genomics, Inc. (TXG) Snapshot price: $46.4
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +8.94% | 480.2K |
$80.13 | -$116,188,500.00 | 5.85M |
May 12 - May 13
| |||
Form 4
| +59.35% | 2M |
—
|
—
| 5.37M |
May 6
| |||
Form 4
| +14.67% | 392.26K |
—
|
—
| 3.07M |
Apr 22 - Apr 23
| |||
Form 4
| +13.29% | 387.81K |
—
|
—
| 3.3M |
Apr 13 - Apr 14
| |||
Form 4
| +1,157.66% | 2.17M |
—
|
—
| 2.36M |
Mar 24
| |||
Form 4
| +15.36% | 559K |
$59.00 | -$44,250,000.00 | 4.2M |
Mar 4 - Mar 18
| |||
Form 4
|
∞
| 187.5K |
$39.00 | $7,312,500.00 | 187.5K |
Sep 12 - Sep 16
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
AERIE PHARMACEUTICALS INC No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -18.10% | -1.00M |
$17.07 | -$17,070,000.00 | 4.52M |
Feb 27
| |||
Form 3/A
|
—
|
0
|
—
|
—
|
0
| ||||
Form 4
| +1.94% | 115.9K |
$18.46 | $2,140,890.00 | 6.09M |
Sep 4 - Sep 5
| |||
Form 4
| +3.33% | 75K |
$21.00 | $1,574,741.00 | 2.33M |
Aug 30 - Sep 3
| |||
Form 4
| +2.09% | 46.15K |
$23.45 | $1,082,449.25 | 2.25M |
Aug 21 - Aug 23
| |||
Form 4
| +7.50% | 153.85K |
$23.88 | $3,673,288.98 | 2.2M |
Aug 16 - Aug 20
| |||
Form 4
| +19.13% | 539.55K |
$24.34 | $13,341,170.45 | 3.36M |
Aug 12 - Aug 14
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
Form 4
| -0.55% | -20.00K |
$55.95 | -$1,119,000.00 | 3.62M |
May 26
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
Form 4/A
| -1.48% | -50.00K |
$40.34 | -$2,016,995.00 | 3.32M |
Oct 6
| |||
Form 4
| -1.48% | -50.00K |
$40.34 | -$2,016,995.00 | 3.32M |
Oct 6
| |||
Form 4/A
|
—
|
0
|
—
|
—
|
0
| ||||
Form 3/A
|
—
|
0
|
—
|
—
|
0
| ||||
Form 4
| +17.27% | 250K |
$17.50 | $4,375,000.00 | 1.7M |
Jul 22
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Aimmune Therapeutics, Inc. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
Form 4
| -5.40% | -240.00K |
$15.23 | -$3,654,720.00 | 4.2M |
May 31
| |||
Form 4
| +7.73% | 25.48K |
$19.65 | $500,900.03 | 355.02K |
Aug 24
| |||
Form 4
|
∞
| 4.42M |
$16.12 | $5,349,198.76 | 4.42M |
Aug 11
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||